Sbir phase II: a bacterial intracellular delivery platform for liver cancer
Ended Cooperative Agreement Awarded Last action
- Award ID
- 2035560
- Recipient
-
Ernest Pharmaceuticals, Inc. UEI MKSZL7C5T1G5
- Awarding agency
-
Division of Industrial Innovation
National Science Foundation
- Obligated
- $1,000,000
Award facts
- Assistance listing
- 47.041 Engineering
- Completion date
- Place of performance
- Amherst, MA 01003, USA
Award details come from USAspending.gov.
About this award
Ernest Pharmaceuticals, Inc. was awarded a $1,000,000 cooperative agreement from the National Science Foundation under the Engineering program (CFDA 47.041) for the period from January 15, 2021 through December 31, 2022. The award will support the company's development of a bacterial intracellular delivery platform for liver cancer. As a cooperative agreement, the National Science Foundation will collaborate with Ernest Pharmaceuticals on this research conducted at the company's facility in Amherst, MA. The Engineering program seeks to improve quality of life and economic strength through fostering innovation in engineering research. This award aims to advance that goal by furthering biomedical engineering research applicable to treating liver cancer.
Quick answers
Who received award 2035560?
2035560 was awarded to Ernest Pharmaceuticals, Inc. by Division of Industrial Innovation (National Science Foundation) on January 15, 2021.
How much is award 2035560 worth?
$1,000,000 has been obligated on 2035560.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award